Max Planck Society partners with Sanofi to develop innovative solutions for restoring vision

New collaboration reinforces Sanofi’s translational discovery platform for retinal diseases

September 15, 2011

Max Planck Society (Max-Planck-Gesellschaft), Germany’s leading basic research organization, announced today that it has signed with Fovea Pharmaceuticals, the Ophthalmology Division of Sanofi, a research collaboration and license agreement to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.


About the Max Planck Society and Max Planck Institutes
The Max Planck Society is an independent, non-profit research organization. The primary goal of the Max Planck Society is to promote research at its own institutes. The currently 80 Max Planck Institutes (MPIs) conduct basic research in the natural sciences, life sciences, social sciences, and the humanities. Max Planck Institutes focus on research fields that are particularly innovative, or that are especially demanding in terms of funding or time requirements The Max Planck Society is Germany's most successful research organization. Since its establishment in 1948, no fewer than 17 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide.

About Max Planck Innovation
Max Planck Innovation (MI) is the technology transfer organization of the Max Planck Society (MPG). MI markets patents and technologies to industry and advises Max Planck scientists to establish new start-ups. Every year, Max Planck Innovation evaluates about 150 invention disclosures. In the last 30 years, MI accompanied around 3,200 new inventions and completed nearly 1,900 licensing deals. Since the early 90's about 90 spin-off companies were created.

About Fovea Pharmaceuticals, the Ophthalmology Division of Sanofi
Sanofi’s ambition is to become a leader in ophthalmology and to be different through innovative solutions and a patient-centered approach. Fovea Pharmaceuticals, Sanofi’s Ophthalmology Division, has four products in Phase I and II of development. The three products in Phase II (FOV1101, FOV2302 and FOV2304) aim at treating Persistent Allergic form of Conjunctivitis, Acute Macular Edema following retinal vein occlusion and Chronic Macular Edema due to diabetic retinopathy. The fourth product, RetinoStat®, from Sanofi’s partnership with Oxford BioMedica, is currently in Phase I for the treatment of AMD. Created in May 2005, Fovea Pharmaceuticals is a wholly-owned subsidiary of Sanofi Group since 2009, and is based in Paris on the premises of the Vision Institute. For more information, please visit:

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Go to Editor View